Post-chemotherapy cognitive impairment overview

Jump to navigation Jump to search

Post-chemotherapy cognitive impairment Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Post-chemotherapy cognitive impairment from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Post-chemotherapy cognitive impairment overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Post-chemotherapy cognitive impairment overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Post-chemotherapy cognitive impairment overview

CDC on Post-chemotherapy cognitive impairment overview

Post-chemotherapy cognitive impairment overview in the news

Blogs on Post-chemotherapy cognitive impairment overview

Directions to Hospitals Treating Post-chemotherapy cognitive impairment

Risk calculators and risk factors for Post-chemotherapy cognitive impairment overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In medicine, post-chemotherapy cognitive impairment (also known as chemotherapy-induced cognitive dysfunction or, colloquially, as chemo brain or chemo fog) describes the cognitive impairment that can result from chemotherapy treatment. Approximately 20-30% of people who undergo chemotherapy experience some level of post-chemotherapy cognitive impairment. The phenomenon first came to light because of the large number of breast cancer survivors who complained of changes in memory, fluency, and other cognitive abilities that impeded their ability to function as they had pre-chemotherapy.

Although the causes (and indeed, existence) of post-chemotherapy cognitive impairment have been a subject of debate, recent studies have confirmed that post-chemotherapy cognitive impairment is a real, measurable side-effect of chemotherapy treatment, at least in some patients. A UCLA study published in October 2006 showed that the brains of breast cancer survivors who were treated with chemotherapy have to work harder to perform tasks than survivors whose treatment was surgical. Even more recently, Japanese researchers have demonstrated that a year after treatment, the brains of cancer survivors treated with chemotherapy had physically shrunk; those of people not treated with chemotherapy had not.

Post-chemotherapy cognitive impairment comes as a surprise to many cancer survivors. Often, survivors think their lives will return to normal when the cancer is gone, only to find that the lingering effects of post-chemotherapy cognitive impairment impede their efforts. Working, connecting with loved ones, carrying out day-to-day tasks—all can be very challenging for an impaired brain. Although post-chemotherapy cognitive impairment appears to be temporary, it can be quite long-lived, with some cases lasting 10 years or more.

References